BioNTech raises $250 million from investors including Temasek

BioNTech said Singapore's state investment company Temasek and other investors are injecting $250 million into the German biotech firm through a private placement.

The company, which is developing a Covid-19 vaccine, said the transaction includes the purchase of about $139 million in ordinary shares and a $112 million investment in 4-year mandatory convertible notes.